Support line (toll-free) (844) 835-4325 | Events help (608) 828-8852 | Community

Free To Breathe - A Partnership For Lung Cancer Survival

participant Login


Featured Clinical Trial of the Week: A Brand New Drug for ALK-Positive NSCLC

  • August 16 2013

    Share |
    Featured Clinical Trial of the Week: A Brand New Drug for ALK-Positive NSCLC

    The Lung Cancer Mutation Consortium (managed through the National Lung Cancer Partnership) recently reported that 62% of the approximately 1,000 advanced lung cancer patients examined had identifiable genetic mutations or changes that "drive" their lung cancer. Remarkably, patients who were treated with drugs that targeted their genetic driver lived, on average, 1.4 years longer than patients for whom a mutation wasn't identified.

    CH5424802 targets the ALK mutation, which is present in 3-5% non-small cell lung cancer cases. In phases I and II of this clinical trial, researchers will assess the proper dosage for CH5424802 and measure its effectiveness in stopping or reversing tumor growth.



    Non-small cell lung cancer patients with an ALK mutation whose disease has stopped responding to crizotinib are eligible for this clinical trial. Visit for more information on this trial.

    If you’re looking for further information on this and/or other lung cancer clinical trials, please contact our Clinical Trials Matching Service, where trained representatives will match your particular cancer and health issues to clinical trials that are available for you.


Leave a comment

Comment Guidelines

Basic HTML formatting permitted -
<ul>, <li>, <strong>, <em>, <a href>, <blockquote>, <code>

©2018 Lung Cancer Research Foundation | Federal Tax ID #14-1935776 | LCRF is a 501(c)(3) public charity.